Tobacco + Addiction
Tobacco, excessive alcohol use, problematic illicit drug use and problem gambling are ‘dangerous consumptions’ that have a significant negative emotional and financial impact on individuals, their families/whanau and the community. Many individuals engage in more than one type of dangerous consumption. The Addiction Research theme investigates innovative, but practical, solutions to reducing these health risks, particularly focusing on priority population groups. Studies test the effectiveness of novel delivery systems, variations in the delivery of standard treatments, or novel treatments, and often utilise the pragmatic community-based trial design to ensure generalisability of the findings to the ‘real world’.
Current research highlights
The harms from gambling can be mild to severe but they are often hidden. Reasons for hiding gambling problems are many, including the feeling of stigma or a sense of shame (whakamā, lagona o le maasiasi) that having a problem with gambling may generate. This means that many people who experience harms and problems from gambling do not readily seek help from the available treatment services, when they may need it. Other reasons for not accessing help can also include, where the services are and difficulty accessing them, the times they are open do not fit, whether they feel culturally appropriate and so on. For these reasons, our research into gambling is focused on developing and testing mobile phone-based applications (apps) that be used by anyone at anytime and anywhere, to help provide evidence-based support.
Our current research project, Manaaki, is a randomised control trial exploring if a cognitive behavioural programme, adapted from an online programme developed by researchers from Deakin University, Australia, is an effective tool for helping people experiencing problems with their gambling but who don’t access or use gambling treatment services but do want support to help them gain control, and either stop gambling altogether or stop their harmful gambling. Manaaki uses evidence-based interventions to help improve your motivation and confidence to gamble less, and help grow your skills to gamble less by changing the way you think and behave. Research indicates that these are effective strategies in helping people to take more control and stop the gambling that is causing the harms.
Where are we at? Manaaki is in the last phase of being tested and it will be ready for evaluating from early 2020. If you want to know more about this research please contact the research team. If you want to know when Manaaki is ready to be tried, please register your interest here and we will let you know when you can download it and help us evaluate if it is effective.
mCessation Cook Islands
Building on the STOMP mCessation programme and recent work in Samoa (TXTTaofiTapaa) this WHO funded project involves the adaptation and piloting of the mCessation programme for the Cook Islands. Working with the local Cook Islands Ministry of Health and key stakeholders the existing programme will be adapted, translated and then piloted and evaluated in the Cook Islands providing a simple and accessible smoking cessation intervention.
NZ Step Away Trial
A randomised-controlled clinical trial investigating whether six-months assess to the ‘NZ Step Away’ app can reduce the frequency of alcohol abuse and increase engagement with substance abuse related health services by hazardous drinkers.
This feasibility project is funded by the Health Research Council of New Zealand and was designed in collaboration with external investigators Dr Suzanna Galea-Singer (Waitemata DHB) and Professor Patrick Dulin (University of Alaska Anchorage). The study will finish in December 20198
For more information contact Associate Professor Natalie Walker (Principal Investigator)
RAUORA is a single-blind, randomised, non-inferiority randomised controlled trial examining the effectiveness, safety and cost-effectiveness of cytisine (Tabex®) compared to varenicline (Champix®) for smoking cessation in Māori and whānau of Māori. The trial is led by Associate Professor Natalie Walker and is a collaboration with the School of Pharmacy, University of Auckland, Brunel University London, and the Lakes District Health Board. The trial is aiming to enrol 2,140 participant who are daily smokers (≥18 years), live in the Lakes District Health Board region of NZ, self-identify as Māori or whānau of Māori, are motivated to quit, and are eligible for subsidised varenicline under special authority conditions. The trial is funded by a three-year grant from the Health Research Council of NZ.
In China, around 60% of men aged 25-44 years smoke tobacco. This group (about 250 million people in number) is the target of a study led by PhD student Jinsong Chen. His supervisor, Professor Chris Bullen says “Jinsong has developed and tested a unique smartphone smoking cessation app within WeChat, China’s most popular social media platform. Remarkably, all development work with app end users and a pilot randomised trial to evaluate effectiveness on smoking status has been conducted digitally –remotely –with no face to face contact.” The results of the trial are due later this year.
A randomised-controlled clinical trial designed to evaluate the effectiveness and safety of an adaptive treatment for smoking cessation in people with mental health problems and addictions.
The project is funded by the Health Research Council of New Zealand and was designed in collaboration with external investigators Dr George Laking, Dr Susanna Galea and Dr David Newcombe.
For more information contact Professor Chris Bullen (Principal Investigator).
Previous Research Highlights
ASCEND-2 is a three-arm, pragmatic, community-based clinical trial designed to evaluate the effectiveness and safety of combining nicotine patches with a second generation e-cigarette (with and without nicotine) plus behavioural support, on smoking abstinence. The trial recruited 1124 participants and has recently finished. The trial protocol is published and available here. A publication of the main findings is currently under review.
CASCAID is a three-arm, pragmatic, community-based, non-inferiority trial designed to evaluate the effectiveness and safety of cytisine compared to usual Quitline care (Nicotine patches and/or gum or lozenges). The trial was undertaken between 2011 and 2013 and recruited 1310 participants. The main findings of the trial were published in 2014 the New England Journal of Medicine, and are available here.
NIHI leads the Cochrane Systematic Review on mobile phone‐based interventions for smoking cessation. The review collates the evidence on the effectiveness of mobile phone‐based smoking cessation interventions. The first review took place in 2009 with updates in 2012, 2016 and another underway currently. For more information please contact Associate Professor Robyn Whittaker.
The LABEL study involved a qualitative study (with seven focus groups) and a four-arm clinical trial (involving 600 people). Both studies investigated the impact of energy labelling of alcoholic beverages on consumers perceptions, and likely purchase and consumption behaviour. Publications of the main findings from each study are in press.
mCessation handbook for WHO
Associate Prof Robyn Whittaker is an invited expert on the WHO’s ‘Be Healthy Be Mobile’ global mHealth initiative for non-communicable diseases. In particular, Dr Whittaker wrote the first handbook on mCessation that has been used by several countries to implement national or large scale mCessation programmes in collaboration with BHBM. Drs Whittaker and Dobson recently reviewed these implementations and updated the mCessation handbook for the WHO in collaboration with an international expert group.
SPGeTTI- A Gambling Harm Reduction Study
The goal of this research was to explore and test if using the SPGeTTI app could help participants stop or reduce the gambling harms being experienced. SPGeTTI was designed to deliver a package of tailored support messages and information to anyone who is, or thinks they may be, experiencing harms from gambling. This project had ethical approval, is registered with ANZCTR and was funded by the Ministry of Health.
There were 5 inter-related phases in the SPGeTTI Phase II project.
- Estimating smartphone ownership and patterns of use among people with problem gambling.
- Estimating likely recruitment, retention and sample size for the trial.
- Developing content, features and functions.
- Testing content, features and functions for face validity and acceptability, technical refinement and testing.
- Evaluating its effectiveness.
To read about the findings of the formative phase, click here.
This study was NIHI's original text message smoking cessation intervention and was tested in a national RCT in 2002. A Māori version of the text message programme was developed by Māori co-investigators and offered to Māori participants. The trial found that those participants receiving STOMP were twice as likely to quit as those in the control group. STOMP was shown to be as effective for Māori participants as for non-Māori participants.
This programme was implemented as a national Txt2Quit service run by HSAGlobal and The Quit Group as part of the national MoH-funded cessation programme for many years (until the national cessation contract was changed). It is also still run as KickButts in the USA.
TXTTaofiTapaa (TXT Stop Smoke)
This study involved the adaption and pilot testing of an mCessation tool to support tobacco control goals in Samoa including to increase quit attempts and reduce tobacco use. The study funded by Health Research Council of New Zealand and the New Zealand Ministry of Foreign Affairs and Trade involved extensive formative work in the local Samoan population. This led to the development of TXTTaofiTapaa, an adaption of the STOMP text message smoking cessation programme, which was piloted in 100 people in Samoa. For more information please contact Associate Professor Robyn Whittaker.